Lupin and Yabao announce strategic partnership in China
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures
Lupin today announced that it has entered into a strategic partnership with Yabao Pharma to meet the growing demand for quality drugs with paediatric formulations in the Chinese markets.
The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures. The latest Chinese paediatric pharma market report indicates that the market for paediatric drugs in China is expected to reach 210 billion CNY ($33 billion) in 2021, growing at a rate of 9.23 per cent, Lupin said in a statement.
Dr Fabrice Egros, President – Corporate Development and Growth Markets, Lupin, said in the statement, “……..In addition to marketing our paediatric products in the Chinese market, we intend to expand our collaboration in other strategic therapeutics areas such as cardio-metabolic, central nervous system and gastro-enterology.”